Audible Article by Noele P. Nelson and Trudy V. Murphy

Audible Article by Albert J. Czaja

Audible Article by Michael Ronan Lucey

Audible Article by Michael R. Lucey and John M. Vierling

Audible Article by Giorgina Mieli-Vergani and Diego Vergani

The Model for End-Stage Liver Disease (MELD) score uses the international normalized ratio, creatinine, and total bilirubin to predict 3-month mortality risk, making it a relatively easy and objective measurement for organ allocation, however concerns about equitable distribution remain.

HBV was once regarded as a contraindication for liver transplantation. In the last 20 years advances such as HBIG and LAM have made HBV infection one of the best indications for LT, although cost and availability of prophylactic therapies can be challenges.

Successful treatment of HCV improves survival after liver transplantation, but antiviral therapy for patients awaiting transplantation or on immunosuppression after LT continues to be clinically challenging. In this era of rapidly changing HCV therapy, Dr. Elizabeth Verna explains strategies for eliminating hepatitis C in pre- and post-LT settings.

Pioneered in pediatric patients in the late 1980s due to insufficient appropriately sized liver donors and high mortality among children on the organ waiting list, living donor liver transplantation is now also employed in the adult patient population.

The rising use of expanded criteria donors in an aging patient population makes careful selection of donors and recipients increasingly important. Understand the complex interplay between factors such as donor age, risk index, sex, race, and genetics, as well as the etiology of the liver disease in the recipient, to improve patient outcomes.